Kinnate Biopharma adds two candidates to pipeline, provides cash runway guidance

Kinnate Biopharma announced the addition of two new internally developed next generation development candidates to its targeted oncology pipeline – a brain penetrant mitogen-activated protein kinase inhibitor and a highly selective mesenchymal-epithelial transition factor gene inhibitor. The company also announced that it had approximately $231M of cash, cash equivalents and investments as of March 31, 2023, which is anticipated to fund planned operations into early 2025. "We are proud of our growing portfolio of precision oncology programs comprised of highly selective therapeutics with optimized drug properties designed to address broad alteration coverage, resistance mechanisms and now brain penetrance. The addition of Kinnate’s next generation MEK and c-MET research programs to our development pipeline illustrates the productivity of our capability-based discovery engine, which is delivering on our goal of bringing forward one new IND a year. Targeted therapies have tremendous potential to help patients, but only about ten percent of patients with advanced or metastatic cancer are eligible for currently approved targeted therapies. We look forward to continued progress powered by our Kinnate Discovery Engine and the impact we can have on the lives of those battling cancer," said Robert Kania, Ph.D., senior vice president, drug discovery, Kinnate Biopharma.